CoChat

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors

Open access
Allegrezza, Michael J., Rutkowski, Melanie R., Stephen, Tom L., Svoronos, Nikolaos, Tesone, Amelia J., Perales-Puchalt, Alfredo, Nguyen, Jenny M., Sarmin, Fahmida, Sheen, Mee R., Jeng, Emily K., Tchou, Julia, Wong, Hing C., Fiering, Steven N., Conejo-Garcia, Jose R. · 2016 · Cancer Research
Cited by 33

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Many signal transduction inhibitors are being developed for cancer therapy target pathways that are also important for the proper function of antitumor lymphocytes, possibly weakening their therapeutic effects. Here we show that most inhibitors targeting multiple signaling pathways have especially strong negative effects on T-cell activation at their active doses on cancer cells. In particular, we found that recently approved MEK inhibitors displayed potent suppressive effects on T cells in vitro. However, these effects could be attenuated by certain cytokines that can be administered to cancer patients. Among them, clinically available IL15 superagonists, which can activate PI3K selectively in T lymphocytes, synergized with MEK inhibitors in vivo to elicit potent and durable antitumor responses, including by a vaccine-like effect that generated resistance to tumor rechallenge. Our work identifies a clinically actionable approach to overcome the T-cell–suppressive effects of MEK inhibitors and illustrates how to reconcile the deficiencies of signal transduction inhibitors, which impede desired immunologic effects in vivo. Cancer Res; 76(9); 2561–72. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2808

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 33

Metadata

Authors
Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Tesone, A. J., Perales-Puchalt, A., Nguyen, J. M., Sarmin, F., Sheen, M. R., Jeng, E. K., Tchou, J., Wong, H. C., Fiering, S. N., & Conejo-Garcia, J. R.
Venue
Cancer Research
Published
2016-05-01
Volume
76
Issue
9
Pages
2561-2572
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2299115991
Cited by
33
References
9
FWCI
2.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2808
The paper
Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Tesone, A. J., Perales-Puchalt, A., Nguyen, J. M., Sarmin, F., Sheen, M. R., Jeng, E. K., Tchou, J., Wong, H. C., Fiering, S. N., & Conejo-Garcia, J. R. (2016). IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2808

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.